Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Farrukh T. Awan, November McGarvey, Abraham Lee, Ken Imanak, Simran K. Tiwana, Sean Garrison, Masoom Priyadarshini

Blood (2023) 142 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2023-178048

Published: 2023

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Farrukh T. Awan, Aleksandra Vidisheva, Matia Saeedian, Murat Kurt, Simran K. Tiwana, Masoom Priyadarshini

Blood (2023) 142 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2023-178058

Published: 2023

Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2023-177989

Published: 2023

Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2023-178017

Published: 2023

Journal Articles

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Farrukh T. Awan, Gaurav A. Deshpande, Trong Kim Le, Sean Garrison, Simran K. Tiwana, Masoom Priyadarshini

Blood (2022) 140 (Supplement 1): 7028–7029.

https://doi.org/10.1182/blood-2022-159195

Published: 2022

NARROW

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Email alerts

ASH Publications

American Society of Hematology

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only